CONTINUE

Treatment of urinary incontinence associated with urethral sphincter insufficiency in the bitch.

LABORATORY
FATRO IBERICA

PHARMACEUTICAL FORM
Oral solution (Sol.o.)
Phenylpropanolamine 40mg/ml.

PHARMACOLOGICAL PROPERTIES
The clinical effect of phenylpropanolamine in urinary incontinence is based on its ability to stimulate a-adrenergic receptors. This causes an increase, and a stabilization of the closure pressure in the urethra, which is mainly innervated by adrenergic nerves.
In dogs, the plasma half-life of phenylpropanolamine is approximately 3 hours, with maximum plasma concentration reaching approximately one hour after administration.
When the drug is administered to dogs in a fasted state, there is a significant increase in bioavailability.

Indications: AND TARGET SPECIES
Treatment of urinary incontinence associated with urethral sphincter insufficiency in the bitch.
Efficacy has been demonstrated only in ovariohysterectomized bitches.

CONTRAINDICATIONS
Do not use to treat inappropriate urination problems attributable to behavioral disturbances.
Do not use in animals treated with non-selective monoamine oxidase inhibitors.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Special care should be taken when treating animals with severe renal or hepatic insufficiency, diabetes mellitus, hyperadrenocorticism, glaucoma, hyperthyroidism, or other metabolic disorders.

SIDE EFFECTS
Sympathomimetics can produce a wide variety of effects, many of which mimic the reactions of excessive stimulation of the sympathetic nervous system. (eg effects on heart rate and blood pressure). Therefore, it should be used with caution in animals with cardiovascular disease.
Dizziness and agitation have also been occasionally observed. In very rare cases hypersensitivity may occur.

ROUTE OF ADMINISTRATION
Oral administration.

POSOLOGY
Dogs: The recommended dose is 1 mg of phenylpropanolamine/kg bw 3 times a day, in food (equivalent to 0,1 ml of medication per 5 kg bw 3 times a day).
Absorption of the drug is increased when administered to dogs in an empty stomach.

SPECIAL PRECAUTIONS
Care should be taken when co-administering this medication with other sympathomimetic, anticholinergic, tricyclic antidepressant, or specific monoamine oxidase type B inhibitors.
Do not use during pregnancy or lactation.

Presentation:
Box with a 50 ml bottle and a dispenser

See technical sheet